LeMaitre Vascular (LMAT) vs NovoCure (NVCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
NovoCure (NVCR) has outperformed LeMaitre Vascular (LMAT) over the past year, losing 0.9% versus a loss of 8.6%. Over five years, LMAT leads with a +48.0% price change compared with -87.3% for NVCR. LeMaitre Vascular is the larger company by market cap ($1.82 billion vs $1.66 billion), about 1.1 times the size.
LeMaitre Vascular pays a dividend yielding 1.13%, while NovoCure does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LMAT | NVCR |
|---|---|---|
| Share price | $79.64 | $14.22 |
| Market cap | $1.82B | $1.66B |
| 1-day change | +0.42% | -3.00% |
| YTD return | -2.21% | +9.98% |
| 1-year return | -8.62% | -0.91% |
| 5-year return | +48.02% | -87.33% |
| P/E ratio (TTM) | 27.94 | — |
| Forward P/E | 25.05 | — |
| EPS (TTM) | $2.85 | $-1.30 |
| Dividend yield | 1.13% | 0.00% |
| Annual dividend | $0.90 | $0.00 |
| 52-week high | $118.01 | $21.45 |
| 52-week low | $78.22 | $9.82 |
| Distance from 52-week high | -32.51% | -33.71% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +34.35% | +88.89% |
| Average volume | 330.14K | 1.42M |
| Shares outstanding | 22.87M | 116.45M |
| Employees | 646 | 1,605 |
| Sector | Healthcare | Health Care |
| Industry | Medical Instruments & Supplies | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LeMaitre Vascular offers a meaningfully higher dividend yield (1.13% vs 0.00%).
- The two companies sit in different sectors: LeMaitre Vascular in Healthcare and NovoCure in Health Care.
About LeMaitre Vascular
LMAT stock →LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific.
Healthcare · Medical Instruments & Supplies · 646 employees
About NovoCure
NVCR stock →NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
Health Care · Medical/Dental Instruments · 1,605 employees
LMAT vs NVCR FAQ
Which is bigger, LeMaitre Vascular or NovoCure?
LeMaitre Vascular (LMAT) is larger, with a market capitalization of $1.82B compared with $1.66B for NovoCure (NVCR).
Which stock has performed better over the past year, LMAT or NVCR?
NVCR returned -0.91% over the past 12 months, compared with -8.62% for LMAT (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, LeMaitre Vascular or NovoCure?
LeMaitre Vascular pays a dividend yielding 1.13%, while NovoCure does not currently pay a regular dividend.
Are LeMaitre Vascular and NovoCure in the same industry?
No. LeMaitre Vascular is in the Healthcare sector, while NovoCure is in Health Care.